March 18, 2022

Clarification of CAR-T Cell Immunotherapy Billing

It has come to our attention that there is some confusion as to how the CAR-T Cell drug therapies, Kymriah (KYM), Yescarta (YES), and Tecartus (TEC) (hereafter [CAR-T Drug]) should be billed. The transplant specialty contract states the following in regards to these drugs:

“The [CAR-T Drug] will be reimbursed through the contract when administered in an inpatient setting only and is available for purchase through the 340B Drug Pricing Program for the treatment of both pediatric and adult patients with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. The [CAR-T Drug] will be billed with Q code QXXXX or QYYYY. [CAR-T Drug] administered in an outpatient setting will be reimbursed outside of the Transplant Contract.”

To clarify, for transplant reimbursement, CAR-T Drugs must be administered in an inpatient setting and billed as a carve out on an inpatient UB with only the drug codes.